Please assess the completion status of the following clinical trial:

Trial Title: A Phase I, Open-Label, Multicentre Study to Evaluate the Safety, Tolerability and Pharmacokinetics of MEDI4736 in Patients With Advanced Solid Tumours

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* In the dose-escalation phase: patients with advanced solid tumors refractory to standard treatment, intolerant of standard treatment, or for which no standard therapy exists.~In the dose-expansion phase: histologically- or cytologically-confirmed advanced or metastatic biliary tract cancer (BTC), esophagus cancer(EC) (squamous cell carcinoma) or squamous cell carcinoma of the head and neck (SCCHN). - men or women. - Eastern Cooperative Oncology Group (ECOG) status of 0 or 1. - Adequate organ and marrow function. - Subjects must have at least 1 measurable lesion. - Available archived tumor tissue sample. - Willingness to provide consent for biopsy samples.~Exclusion Criteria:~* Any prior Grade ≥ 3 irAE while receiving immunotherapy - Prior exposure to any anti-PD-1 or anti-PD-L1 antibody - Active or prior documented autoimmune disease within the past 2 years - History of primary immunodeficiency - Symptomatic or untreated central nervous system (CNS) metastases requiring concurrent treatment - Women who are pregnant or lactating - Uncontrolled intercurrent illness - Known history of tuberculosis - Known to be human immunodeficiency virus (HIV) positive - Hepatitis B or C infection - Other invasive malignancy within 5 years

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 130 Years
- Healthy Volunteers: f

Study Arms:
- MEDI4736 Q2W (Type: EXPERIMENTAL): Evaluate MEDI4736 given every 2 weeks
- MEDI4736 Q3W (Type: EXPERIMENTAL): Evaluate MEDI4736 given every 3 weeks
- MEDI4736 Dose Expansion (Type: EXPERIMENTAL): evaluate MEDI4736 given every 2 weeks
- MEDI4736 Q4W (Type: EXPERIMENTAL): Evaluate MEDI4736 given every 4 weeks
- MEDI4736 combined with another drug (Type: EXPERIMENTAL): evaluate MEDI4736 in combination with another drug given every 4 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).